News und Analysen
Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019
Clovis
Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary,
unaudited revenues for the fourth quarter and full year ended December
31, 2019. The financial
Clovis Oncology Announces Debt Refinancing Transaction
Clovis Oncology, Inc. (NASDAQ: CLVS) (the “Company”) announced today that on January 6, 2020 it priced a registered direct offering (the “Share Offering”) of an aggregate of 17,777,679 shares (the
Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE:
Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery
Cellectis
(Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth:ALCLS; Nasdaq:CLLS), a
biopharmaceutical company focused on developing immunotherapies based on
gene-edited
MEDICREA® Secures 7 New US Patents Around Its Proprietary Platform Technology UNiD™ ASI And Reinforces Barriers to Entry for Competitors
The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX
Best Market –MRNTF), pioneering the transformation of spinal surgery
through Artificial Intelligence,
The Medicines Company Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible Senior Notes due 2024
The Medicines Company (the “Company”) today provided notice of a Make-Whole Fundamental Change to holders of its (i) 2.50% Convertible Senior Notes due 2022 (the “2022 Notes”), (ii) 2.75%
Biofrontera: Bald könnte es Top-Neuigkeiten geben
Der Dermatologie-Spezialist Biofrontera (WKN: 604611) sah sich zuletzt einer schwindenden Umsatzdynamik gegenüber. Einer der Schlüsselfaktoren ist der Absatz des verschreibungspflichtigen
Premier Inc. Analysis: Complications & Common Chronic Conditions Increase Hospitals’ Childbirth Costs by 20 Percent or More
U.S. hospitals could save upwards of 20 percent in costs for complicated childbirths, according to a nationally representative analysis by Premier Inc. (NASDAQ: PINC). The increased costs
Dexcom to Present at 38th Annual J.P. Morgan Healthcare Conference
DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 38th annual J.P. Morgan Healthcare
Clinigen and Orphazyme launch an Early Access Program for arimoclomol in patients with Niemann-Pick disease type C
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Orphazyme A/S (ORPHA.CO, ‘Orphazyme’), a global biopharmaceutical company dedicated to
Charles River Laboratories Completes the Acquisition of HemaCare Corporation
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of HemaCare Corporation (OTCMKTS: HEMA) for approximately $380
Illumina and Pacific Biosciences Announce Termination of Merger Agreement
Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on
NanoString to Present at the 38th Annual JP Morgan Healthcare Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced that the company’s management is scheduled to present at the 38th
Pulmatrix: NBC-Empfehlung explodiert nach Big-Pharma-Deal
Für den No Brainer Club überträgt sich das gigantische Momentum von Ende 2019 ohne Unterbrechung ins neue Jahr: Mit Pulmatrix (WKN: A2PD3T) explodiert heute einer der letzten unten gebliebenen No
Agilent Expands Cross-Vendor CDS Instrument Control
Agilent Technologies Inc. (NYSE: A) today announced the latest implementation of its mutual compatibility philosophy. Now, joint customers of Agilent Technologies and Thermo Fisher Scientific can
LION E-Mobility: Nach dem Deal ist vor der Rallye?
LION E-Mobility (WKN: A140QA) hatte mit der kanadischen Firma "The Lion Electric Co." vor Weihnachten einen „Multimillionen-Serienliefervertrag über BMW-Batterien“ geschlossen. Nun gibt das
Navidea Biopharmaceuticals Obtains Partial Dismissal of Claims in New York
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Agilent Compliance Services Voted No. 1 in Global Survey
Agilent Technologies Inc. (NYSE: A) today announced that the company’s ability to help laboratories comply with government regulations has been ranked second to none in a global survey.
Cell
Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled
Cidara und Otonomy: Weitere NBC-Favoriten knallen durch die Decke
Aktien von Cidara Therapeutics (WKN: A14R2R) und Otonomy (WKN: A119VZ) gehörten vergangene Woche mal wieder zu den Gewinnern im Biotech-Sektor. Stehen hier ähnliche Entwicklungen an wie jüngst bei
Paion: Erste Zulassung zum Greifen nah - jetzt einsteigen?
Weltweit laufen bei Paion (WKN: A0B65S) Zulassungsanträge für den potenziellen Anästhesie-Blockbuster Remimazolam, doch die Aktie notiert auf Langzeittief. Die erste Zulassung des Präparatss könnte
LION E-Mobility: Serienliefervertrag für E-Schulbusse fix
LION E-Mobility (WKN: A140QA) wird Serienlieferant von Batterien für E-Schulbusse und E-LKWs. Dazu schloss das Unternehmen einen „potentiellen Multimillionen-Serienliefervertrag über BMW-Batterien“.
Qiagen: Übernahme geplatzt – so kann es jetzt weitergehen
Qiagen-Aktien (WKN: A2DKCH) verbilligen sich heute um -18,93% auf 30,02 Euro. Der Grund sind gescheiterte Übernahmegespräche.
Die Gespräche mit möglichen Übernahme-Interessenten würden nun beendet
Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference
Novocure (NASDAQ: NVCR) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak
QIAGEN Concludes Strategic Alternatives Review; Decides to Focus on Stand-Alone Business Strategy to Drive Future Value Creation
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) today announced that it has concluded the previously announced review of potential strategic alternatives, and